t*******o
发帖数: 1464 | 1 http://www.thestreet.com/story/10766153/1/alkermes-vivitrol-gets-speedy-fda-review.html
Alkermes(ALKS) will hear from U.S. drug regulators by Oct. 12 about an
approval decision for the company's drug to treat patients addicted to
opioid painkillers, the company said.
October is shaping up to be busy month for Alkermes. On Oct. 22, the FDA is
also expected to issue an approval decision for Bydureon, the company's long
-acting diabetes drug which is partnered with Amylin Pharmaceuticals and Eli
Li... 阅读全帖 |
|
t******g
发帖数: 462 | 2 Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. dropped in
early trading after they were rebuffed a second time in a bid to gain
approval of a once-weekly version of the diabetes drug Byetta.
The Food and Drug Administration “blindsided” the companies late yesterday
by calling for a study assessing the heart risks for the new drug Bydureon,
said Phil Nadeau, an analyst with Cowen & Co. in New York.
The FDA restricted the use last month of GlaxoSmithKline Plc’s diabetes
drug Avandi... 阅读全帖 |
|
f**********g
发帖数: 2252 | 3 Bio guys please discuss.
Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol
Dependence
Wednesday 12/08/2010 8:00 AM ET - Businesswire
Related Companies
Symbol Last %Chg
ALKS 11.40 1.29%
As of 10:55 AM ET 12/8/10
Alkermes, Inc. (NASDAQ: ALKS) today announced preliminary results from a
phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates
for the treatment of reward disorders and other central nervous system (CNS)
disorders. The 12-week study was designed to a... 阅读全帖 |
|
|
p***o
发帖数: 714 | 5 Unlike U.S. Food and Drug Administration drug approvals, which are more
precisely timed, the release dates for data from clinical trials is bit
fuzzier, so the timelines here are culled from company guidance when
possible.
The working list of clinical trials expected to complete in 2009 is fairly
long, so expect more information on clinical trials to watch in the coming
weeks.
Company: GTx(GTXI)
Drug/indication: Acapodene for precancerous prostate lesions (high-grade PIN)
Clinical trial event: p... 阅读全帖 |
|
N***i
发帖数: 2063 | 6 http://www.zacks.com/stock/news/37221/Pharma+and+Biotech+Industry+Outlook+-+July+2010
By: Zacks Equity Research
July 20, 2010 | Comments: 0
Recommended this article (2)
ABT | JNJ | PFE | MRK | RHHBY | BMY | SNY | MYL | LLY | GSK | ACL | GILD |
BIIB | AMLN
Print Share
The pharmaceutical industry has witnessed major changes over the past few
quarters, with performance being affected by factors like sluggish
prescription trends, intensifying generic competition and limited late-stage
catalysts. ... 阅读全帖 |
|
f**********g
发帖数: 2252 | 7 Alkermes: ALKS 33 Showed A Clear Effect In Reducing Heavy Drinking In This
Trial
Wednesday 12/08/2010 8:09 AM ET - T
Alkermes: Results Show ALKS 33 Was Generally Well Tolerated
Wednesday 12/08/2010 8:08 AM ET - T |
|
f**********g
发帖数: 2252 | 8 http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioThera... 阅读全帖 |
|
f**********g
发帖数: 2252 | 9 http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioThera... 阅读全帖 |
|
O**I
发帖数: 776 | 10 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
w****r
发帖数: 245 | 11 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
r***s
发帖数: 1805 | 12 批了. 小玩了一个 bull spread, 估计挣不了几个钱.
FDA approves Bydureon from Amylin, Alkermes, Bloomberg says |
|
r***s
发帖数: 1805 | 13 批了. 小玩了一个 bull spread, 估计挣不了几个钱.
FDA approves Bydureon from Amylin, Alkermes, Bloomberg says |
|
h*********y
发帖数: 170 | 14 标准：high p/e potential, high volatility, mid or large cap, RSI < 50, high
future EPS growth
1. Tech
33.8 SLH Solera Holdings Inc. 2.45% Mid
21.6 ATHN athenahealth, Inc. 5.49% Mid
14.6 SATS EchoStar Corp. 2.50% Mid
3.7 LNKD LinkedIn Corporation 4.90% Large
3.1 ROVI Rovi Corporation 4.58% Mid
2.7 DDD 3D Systems Corp. 5.52% Mid
2.6 MSCC Microsemi Corp. 3.32% Mid
2.6 CTRX Catamaran Corporation 3.00% Mid
2.... 阅读全帖 |
|
b*****p
发帖数: 9649 | 15 by http://www.guancha.cn/xiaopengcai
星期五传出来Ariad Pharmaceuticals($ARIA)公司内部董事会开始内斗。目前这家公司
的最大股东是萨瑞莎资本公司（Sarissa Capital）拥有6.9%的股份。自从这家维权对
冲基金公司（Activist Hedge Fund）入主这家公司，市场上就开始有心理准备这场即
将到来震荡。萨瑞莎资本公司的创始人叫Alex Denner，今年45岁，是真正的高富帅啊
。这人麻省理工大学本科毕业，耶鲁大学生物医学工程专业博士，博士毕业后在华尔街
摩根斯坦利（Morgan Stanley）和维京全球投资公司（Viking Global Investors）做
医药和生物科技基金经理，后来拜入卡尔·伊卡恩（Carl Icahn）门下统管医药和生物
科技对冲基金，成为卡尔·伊卡恩门生。这人非常内行专业，很懂得分析生物医药公司
的内在价值并把这种价值体现在商业价值上。2012年羽翼丰满脱离卡尔集团自创萨瑞莎
对冲基金公司。
我在前面2月8日文章“大鱼吃小鱼，小鱼吃虾米”中有提到卡尔·伊卡恩是一个传奇投
资... 阅读全帖 |
|
n***s
发帖数: 897 | 16 BIIB, PRTA are in this growth stocks list
You are good at picking biopharm's winners ,呵呵
ACADIA Pharmaceuticals, Inc. (a)(e)
Agios Pharmaceuticals, Inc. (a)(d)
Alexion Pharmaceuticals, Inc. (a)
Alkermes PLC (a)(e)
Alnylam Pharmaceuticals, Inc. (a)(e)
Amgen, Inc.
Array BioPharma, Inc. (a)(d)
Avalanche Biotechnologies, Inc. (a)
Biogen Idec, Inc. (a)
Bluebird Bio, Inc. (a)(d)(e)
Celgene Corp. (a)
Celldex Therapeutics, Inc. (a)
Cepheid, Inc.... 阅读全帖 |
|
h****J
发帖数: 56 | 17 Major pharmas or biotechs usually don't make bio-degradable polymers or
develop this type of formulations (implants, microspheres, etc) in-house.
They work with external partners. There are many smaller drug delivery
companies or CROs work on that (Alkermes, Brookwood, MacroMed, etc), but
their job opportunities might be less. Some big medical device companies (
Boston Scientific, J&J/Ethicon, etc) may be more interested in your
technical background.
If you just want to find a job, do somethin |
|
|
|
b**********r
发帖数: 1580 | 20 各个方面，越详细越好，尤其是发展前景和其职位的稳定性方面。 |
|
|
m*z
发帖数: 2356 | 22 来自主题: _Stockcafeteria版 - ARNA Sept. 16
FDA advisory panel meetings: Arena Pharmaceuticals'(ARNA) lorcaserin in
obesity and Alkermes'(ALKS) Vivitrol Opioid for opioid addiction. |
|
|
|
Q********8
发帖数: 497 | 25 哦俄哦俄哦额，这个早就研究过了。是VVUS撤出后进驻的选择之一。 |
|
g**********1
发帖数: 399 | 26 almost no hope for alks |
|
y******z
发帖数: 491 | 27 这个最近我就进过一次，好像有insider buy，不过大盘不对只好溜掉。要不要买点10
月靠嘞～ |
|
t*******o
发帖数: 1464 | 28 大盘剧烈动荡的时候， VIX高，option很贵。昨天VIX一下来，call put两边都亏钱。
大家都不傻，11月的option很贵，都在 expect some big up or down。
现在这个世道，保存革命的cash，隐忍活下来最重要。
10 |
|
g******0
发帖数: 1165 | 29 顶 留CASH
俺抓咪咪不再行 留CASH防身吧 |
|
w***y
发帖数: 2537 | 30 【 以下文字转载自 Stock 讨论区 】
发信人: ll111 (Stealth), 信区: Stock
标 题: Events and ER for week August 2-6
发信站: BBS 未名空间站 (Sun Aug 1 22:47:17 2010, 美东)
Monday, Aug. 2
10 a.m.: ISM Manufacturing index on business activity in July, released by
the Institute for Supply Management.
10:15 a.m. Federal Reserve Chairman Ben Bernanke speaking on "challenges for
the economy and state governments."
4 p.m. Treasury Secretary Timothy Geithner speaking on the next steps for
financial reform.
Tuesday, Aug. 3
8:30 a.m.: P... 阅读全帖 |
|
y*****l
发帖数: 5997 | 31 股票:ARNA, VRTX, ATHX, BDSI, CTIC, BCRX, SGEN
http://finviz.com/screener.ashx?v=341&t=ARNA,VRTX,ATHX,BDSI,CTIC,BCRX,SGEN
http://www.thestreet.com/story/10849406/1/biotech-calendar-key-dates-for-september.html
To prepare, here is a calendar of important, potentially stock-moving
biotech events in September:
Phase III or pivotal registration studies that could report results in
September:
* Vertex Pharmaceuticals'(VRTX) hepatitis C drug telaprevir (previously
treated patients.)
* Seattle Gen... 阅读全帖 |
|
S***a
发帖数: 1072 | 32 September's BioPharma Catalyst Calendar
By Lisa LaMotta Sep 01, 2010 2:40 pm
This month could be full of opportunities for biotech and pharmaceutical
investors who know where to look.
•More by Lisa LaMotta
•Forest Faces a Positive-Leaning PanelOrexigen Fattens Its Coffers
With Takeda CashSeptember's BioPharma Catalyst CalendarWhat's the Buzz?
30 top traders on these stocks and more
VVUS 6.33 +0.61 (+10.75%)
FRX 29.20 +1.55 (+5.61%)
CBST 22.52 -0.09 (-0.40%)
... 阅读全帖 |
|
b*****h
发帖数: 783 | 33 多谢包子，
alks和almn是2000年partner的，almn用alks的专利释药技术来开发 long-acting
release formulation of exenatide. 而alks可以获得研究经费和milestone payments
，如果药物上市，Alkermes will also receive a combination of royalty payments
and manufacturing fees based on any future product sales。
2002年 almn又和lilly共同开发exenatide，平分研究费用和market。
所以，如果BYETTA能过，感觉好处大部分属于lilly和almn的。 |
|
K********g
发帖数: 9389 | 34 Type 2 Diabetes
Ninety to 95 percent of the estimated 246 million adults worldwide who
suffer from diabetes have type 2 diabetes.(1) Despite the introduction of
new medications over the last decade, many people with diabetes are unable
to control their blood sugar.(2) An extended-release formulation of
exenatide may provide a new treatment option for patients with type 2
diabetes.
New treatment paradigm: BYDUREON™ (exenatide extended-release for
injectable suspension) is an extended-rele... 阅读全帖 |
|
O**I
发帖数: 776 | 35 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 36 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
v**********m
发帖数: 5516 | 37 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
v**********m
发帖数: 5516 | 38 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
w*******0
发帖数: 13 | 39 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 40 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 41 http://www.thestreet.com/story/11016605/1/biotech-calendars-201
By Adam Feuerstein 02/22/11 - 07:36 AM ES
Stock quotes in this article:HGSI, OPTR, XNPT, SPPI, DRRX, PATH
BOSTON (TheStreet) -- I've updated the 2011 FDA drug approval calendar.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regul... 阅读全帖 |
|
y*****l
发帖数: 5997 | 42 http://www.thestreet.com/_yahoo/story/11215926/1/biotech-calend
Updated with corrected FDA approval decision date for Roche's melanoma drug
Zelboraf. It's Oct. 28, 2011, not Nov. 11, 2011, as previously reported.
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated
and extended through the first quarter of 2012.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory pan... 阅读全帖 |
|
y*****l
发帖数: 5997 | 43 22 Hot Drugs Facing FDA Approval in 2012
By Adam Feuerstein 11/29/11 - 08:55 AM EST
BOSTON (TheStreet) -- Here's your first look at the biotech and
pharmaceutical companies with pending FDA drug approval decisions in 2012.
The calendar on the following pages captures nearly two-dozen U.S.
regulatory events -- FDA drug approvals and advisory panels -- expected
between December 2011 and July 2012. As every savvy biotech investor and
trader knows, the volatility in biotech and drug stocks ramps sig... 阅读全帖 |
|
D******9
发帖数: 2665 | 44 Bydureon Gains EU Approval
Print Share
By: Zacks Equity Research
June 22, 2011 |Comments: 0
Recommended this article (0)
LLY | ALKS | AMLN | NVO
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company
(LLY), and Alkermes, Inc. (ALKS), recently received a boost with the
European Commission granting marketing authorization to Bydureon (exenatide
once-weekly) for the treatment of type II diabetes.
Bydureon is the first once-weekly treatment to gain approval for type II
diabetes.... 阅读全帖 |
|
